FDA Grants Seven Years' Market Exclusivity to Eagle Pharmaceuticals' Ryanodex for the Treatment of Malignant Hyperthermia
February 23, 2015 at 10:24 AM EST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today confirmed that the U.S. Food and Drug Administration (FDA) ...
